Diary - News All news Adocia announces two new multi-hormonal combination projects

Adocia announces two new multi-hormonal combination projects

Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes

BioChaperone® enables combinations of insulin lispro with pramlintide and insulin lispro with exenatide, three hormones approved for the treatment of diabetes.
Medical benefit of such combinations already established in type 1 diabetes clinical trials with separate injections.
New projects aim to offer more efficient therapy to people living with type 1 diabetes without increasing number of injections.
First clinical study expected to start in Q4 2017.

Read the press release

To go further...

See Adocia profil

Headlines

Our members

Adocia obtains additional financial resources to accelerate its growth

October 14^th, 2019

Orphelia Pharma : CHMP has adopted a positive opinion for Ivozall

October 1^st, 2019

Poxel Initiates Phase 1b Multiple Ascending Dose (MAD) Trial for NASH Drug Candidate, PXL065

September 17^th, 2019

All news

Contact

Bâtiment Domilyon - 321, avenue Jean Jaurès - 69007 Lyon

Tel. : 04.72.76.53.30 - Fax : 09.55.91.30.26

info@lyonbiopole.com

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree